Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Phase Ib Trial Evaluating T-DMI with Neratinib in Women with Metastatic HER2+ Breast Cancer
